As of 2025-11-09, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (33.69) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.65 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -1371.4%.
The range of the Relative Valuation is (32.21) - (34.01) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 16.6x | 15.7x |
| Forward P/E multiples | 15.7x - 20.1x | 17.2x |
| Fair Price | (32.21) - (34.01) | (33.69) |
| Upside | -1315.3% - -1383.4% | -1371.4% |
| Date | P/E |
| 2025-11-04 | -1.35 |
| 2025-11-03 | -1.07 |
| 2025-10-31 | -1.10 |
| 2025-10-30 | -1.13 |
| 2025-10-29 | -1.19 |
| 2025-10-28 | -1.19 |
| 2025-10-27 | -1.14 |
| 2025-10-24 | -1.02 |
| 2025-10-23 | -1.08 |
| 2025-10-22 | -1.04 |
| 2025-10-21 | -1.09 |
| 2025-10-20 | -1.10 |
| 2025-10-17 | -0.98 |
| 2025-10-16 | -0.98 |
| 2025-10-15 | -1.01 |
| 2025-10-14 | -0.94 |
| 2025-10-13 | -0.98 |
| 2025-10-10 | -0.99 |
| 2025-10-09 | -1.07 |
| 2025-10-08 | -1.04 |
| 2025-10-07 | -0.97 |
| 2025-10-06 | -1.01 |
| 2025-10-03 | -1.13 |
| 2025-10-02 | -1.30 |
| 2025-10-01 | -1.05 |
| 2025-09-30 | -0.98 |
| 2025-09-29 | -0.92 |
| 2025-09-26 | -0.88 |
| 2025-09-25 | -0.81 |
| 2025-09-24 | -0.80 |
| 2025-09-23 | -0.81 |
| 2025-09-22 | -0.80 |
| 2025-09-19 | -0.75 |
| 2025-09-18 | -0.80 |
| 2025-09-17 | -0.74 |
| 2025-09-16 | -0.78 |
| 2025-09-15 | -0.81 |
| 2025-09-12 | -0.78 |
| 2025-09-11 | -0.74 |
| 2025-09-10 | -0.78 |
| 2025-09-09 | -0.76 |
| 2025-09-08 | -0.78 |
| 2025-09-05 | -0.80 |
| 2025-09-04 | -0.67 |
| 2025-09-03 | -0.72 |
| 2025-09-02 | -0.69 |
| 2025-08-29 | -0.55 |
| 2025-08-28 | -0.38 |
| 2025-08-27 | -0.33 |
| 2025-08-26 | -0.32 |